IsoPet™
RadioGel™ | Yttrium-90 (Y-90) Brachytherapy Products for Veterinary Applications
The IsoPet® Solutions division is focused on bringing RadioGel™ yttrium-90 brachytherapy products to veterinary oncologists to treat dogs, cats and now
horses suffering from cancerous tumors.
There are over 150 million pet dogs and cats, with over 1/3 of the households in the US owning at least one dog, and just under 1/3 owning at least one cat.
IsoPet® Solutions is establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance. The division will also provide product
awareness and education to veterinary oncologists.
Initial treatments were coordinated through the Chair of the Company’s Veterinary Medicine Advisory Board, Dr. Alice
Villalobos.
CEO | President Dr. Mike Korenko stated: “IsoPet® Solutions allows specific resources to focus on the use of our RadioGel™ Yttrium-90 brachytherapy products in the veterinary space. We believe that RadioGel™ is positioned to build a significant presence in the cancer treatment tool-kit of veterinary oncologists.”
Dr. Alice stated: "I am quite excited at the opportunity to work with RadioGel's™ team to integrate their products into the cancer treatments of companion animals. Cancer affects 50% of dogs over age ten and one in four dogs under age ten. For many years, we have been searching for a useable and effective agent such as RadioGel™ Y-90 brachytherapy devices that can be delivered into tumors on an outpatient basis. I believe that veterinary oncologists around the globe will finally have an ideal product line for the treatment of accessible and inoperable tumors."
Learn more about RadioGel's™ first companion animal treatments through a study at Washington State University funded by the Washington State Life Sciences Discovery Fund for the treatment of feline sarcoma.
RadioGel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
